GENLISA™ Human SARS-CoV-2 (Covid-19) Nucleocapsid Omicron Variant (B.1.1.529) Antigen Quantitative TITRATION ELISA

Introduction: The GENLISA ELISA kits are used for assessing the specific biomarker in samples analytes which may be serum, plasma and cell culture supernatant as validated with the kit. The kit employs a sandwich ELISA technique which leads to a higher specificity and increased sensitivity compared to conventional competitive ELISA kits which employ only one antibody. Double antibodies are used in this kit. Intended Use: The GENLISA Human SARS-CoV-2 (Covid-19) Nucleocapsid Omicron Variant (B.1.1.529) Antigen Quantitative TITRATION ELISA kit is used as an analytical tool for quantitative antigen determination of Human SARS-CoV-2 (Covid-19) Nucleocapsid Omicron Variant (B.1.1.529) in human serum and plasma and cell culture supernatant. Principle: The method employs sandwich ELISA technique. Monoclonal antibodies are pre-coated onto microwells. Samples and standards are pipetted into microwells and Human SARS-CoV-2 (Covid-19) Nucleocapsid Omicron Variant (B.1.1.529) present in the sample are bound by the capture antibodies. After incubation the wells are washed and followed by HRP- conjugated Detection Antibody is pipetted and incubated to form a complex. After washing microwells in order to remove any non-specific binding, the substrate solution (TMB) is added to microwells and color develops proportionally to the amount of Human SARS-CoV-2 (Covid-19) Nucleocapsid Omicron Variant (B.1.1.529) in the sample. Color development is then stopped by addition of stop solution. Absorbance is measured at 450 nm.